News

Allulose Patents Granted to Bonumose for Unique Enzymatic Conversion Process

Bonumose is pleased to announce that the U.S. Patent & Trademark Office has issued U.S. Patent No. 11,078,506 for “Enzymatic Production of D-Allulose”.

This patent issuance follows Bonumose’s Allulose U.S. Patent No. 11,053,528 (July 6, 2021) and allulose U.S. Patent No. 10,704,069 (July 7, 2020). Bonumose has been issued additional Allulose patents and/or has patent applications pending in all major sugar-consuming and sugar-producing countries. Bonumose also has a broad patent portfolio for Tagatose production, as well as for related materials and processes.

The global Allulose market recently was described as a “dumpster fire” (Food Navigator-USA, June 28, 2021).

Bonumose’s approach is markedly different from other Allulose producers.

The standard way to produce Allulose involves a low-yield enzymatic conversion of fructose to Allulose – a conversion that is inherently limited because the enzymatic reaction is reversible. There are multiple processing steps, including the following major ones: (1) starch dextrinization; (2) liquefaction to produce glucose; (3) isomerization of glucose to produce a syrup with 42% fructose content (limited yield due to a reversible enzymatic reaction); (4) separation of fructose from glucose and other sugars in the syrup; (5) partial enzymatic conversion of fructose to produce a syrup with 25%-30% Allulose (limited yield due to a reversible enzymatic reaction); (6) separation of Allulose from fructose; and (7) purification and crystallization.

Alternatively, fructose can be produced by (1) hydrolyzing sucrose (sugar), (2) separating the fructose from glucose (theoretical 50% yield), then continuing from step #5 shown above and/or converting the glucose to fructose as in step #3 above.

Bonumose’s patented process is much more streamlined and eliminates several processing steps. After starch dextrinization, Bonumose’s proprietary blend of enzymes combine in an irreversible enzymatic reaction to directly convert maltodextrin to ~90% yields of Allulose. This is followed by relatively simple purification and crystallization for pure granulated Allulose.

In summary, Bonumose starts with a less processed feedstock (maltodextrin instead of fructose) and still achieves Allulose yields that are 3X-4X higher than fructose-to-Allulose conversions.

Due to Bonumose’s patented enzymatic technology breakthrough, as well as Bonumose’s other technical and business model innovations, Bonumose expects to be able to reduce the cost of Allulose to food & beverage producers globally.

In pursuing its mission to make great-tasting, healthy rare sugars affordable for more people around the world, Bonumose will continue to devote the resources necessary to extend and defend its global intellectual property rights.

Recent News

04/01/2025

ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases,  announced the appointment of Laurie Glimcher, M.D., to its Board of Directors, effective immediately. Dr. Glimcher is a distinguished immunologist widely renowned for her work in cancer

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and